Paradigm Biocapital Advisors LP: VAXCYTE INC (PCVX): Quarterly 13F Position History
As of Q1 2026, Paradigm Biocapital Advisors LP reported 4,793,020 shares of VAXCYTE INC (PCVX), worth $278.5M and representing 5.7% of its 13F equity book. Quarter-over-quarter share count change: + 725,000 (+17.8%) . The position first appeared in Q1 2024 and has been disclosed across 9 13F-HR filings in Pactolio's tracked window.
- 4,793,020Shares Held (Latest Filing)
- $278.5MReported Market Value (Latest Filing)
- 5.7%Portfolio Weight (% of 13F Equity Book)
- +725,000Quarter-over-Quarter Share Change
- +$90.8MQuarter-over-Quarter Value Change
- 4,793,020Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 9 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 4,793,020 | +725,000 | +17.8% | $278.5M | 5.7% | $58.1 |
| Q4 2025 | 4,068,020 | +283,265 | +7.5% | $187.7M | 5.0% | $46.1 |
| Q3 2025 | 3,784,755 | +411,918 | +12.2% | $136.3M | 4.0% | $36.0 |
| Q2 2025 | 3,372,837 | +1,676,356 | +98.8% | $109.7M | 4.7% | $32.5 |
| Q1 2025 | 1,696,481 | +273,694 | +19.2% | $64.1M | 2.9% | $37.8 |
| Q4 2024 | 1,422,787 | +795,055 | +126.7% | $116.5M | 4.1% | $81.9 |
| Q3 2024 | 627,732 | +530 | +0.1% | $71.7M | 2.5% | $114.3 |
| Q2 2024 | 627,202 | 612,793 | -49.4% | $47.4M | 1.8% | $75.5 |
| Q1 2024 | 1,239,995 | — | — | $84.7M | 3.0% | $68.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a PCVX position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported VAXCYTE INC (PCVX) on its 13F-HR filing for the period ending 2024-03-31 (Q1 2024). The position has appeared on 9 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in PCVX?
Between Q4 2025 and Q1 2026, Paradigm Biocapital Advisors LP added 725,000 shares of PCVX (+17.8%), bringing the total reported position to 4,793,020 shares at a market value of $278.5M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in PCVX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.